C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-21
DOI
10.1038/s41388-018-0375-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4- O -Glycan to Cancer Cells
- (2016) Chin-Hsien Tsai et al. CANCER RESEARCH
- Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma
- (2016) B. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis
- (2014) Yun Kong et al. GLYCOBIOLOGY
- Identification of a Novel Protein Binding Motif within the T-synthase for the Molecular Chaperone Cosmc
- (2014) Rajindra P. Aryal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
- (2014) Phuc Felix Nguyen-Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity
- (2014) Mei-Chun Lin et al. ORAL ONCOLOGY
- C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization
- (2013) Y.-M. Wu et al. CANCER RESEARCH
- Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology
- (2013) Catharina Steentoft et al. EMBO JOURNAL
- Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Charles M. Rudin et al. Journal of Thoracic Oncology
- Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer
- (2013) E. S. Antonarakis et al. ONCOLOGIST
- Mucin Glycosylating Enzyme GALNT2 Regulates the Malignant Character of Hepatocellular Carcinoma by Modifying the EGF Receptor
- (2011) Y.-M. Wu et al. CANCER RESEARCH
- Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer
- (2011) B. T. Aftab et al. CANCER RESEARCH
- Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family
- (2011) E. P. Bennett et al. GLYCOBIOLOGY
- Emerging Paradigms for the Initiation of Mucin-type ProteinO-Glycosylation by the Polypeptide GalNAc Transferase Family of Glycosyltransferases
- (2011) Thomas A. Gerken et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
- (2010) James Kim et al. CANCER CELL
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants—Hakomori's concepts revisited
- (2007) Reiji Kannagi et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Mucin-type O-glycosylation and its potential use in drug and vaccine development
- (2007) Mads Agervig Tarp et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More